260 related articles for article (PubMed ID: 23002953)
21. Apparent diffusion coefficient mapping using diffusion-weighted MRI: impact of background parenchymal enhancement, amount of fibroglandular tissue and menopausal status on breast cancer diagnosis.
Horvat JV; Durando M; Milans S; Patil S; Massler J; Gibbons G; Giri D; Pinker K; Morris EA; Thakur SB
Eur Radiol; 2018 Jun; 28(6):2516-2524. PubMed ID: 29330631
[TBL] [Abstract][Full Text] [Related]
22. Background Parenchymal Enhancement and Fibroglandular Tissue Proportion on Breast MRI: Correlation with Hormone Receptor Expression and Molecular Subtypes of Breast Cancer.
Öztürk M; Polat AV; Süllü Y; Tomak L; Polat AK
J Breast Health; 2017 Jan; 13(1):27-33. PubMed ID: 28331765
[TBL] [Abstract][Full Text] [Related]
23. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
[TBL] [Abstract][Full Text] [Related]
24. Multiparametric
Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors of early distant recurrence in hormone receptor-positive, postmenopausal breast cancer patients receiving adjuvant tamoxifen therapy: results of a retrospective analysis.
Debled M; MacGrogan G; Brouste V; Mathoulin-Pelissier S; Durand M; Mauriac L
Cancer; 2007 Jun; 109(11):2197-204. PubMed ID: 17450590
[TBL] [Abstract][Full Text] [Related]
26. Fully Automatic Assessment of Background Parenchymal Enhancement on Breast MRI Using Machine-Learning Models.
Nam Y; Park GE; Kang J; Kim SH
J Magn Reson Imaging; 2021 Mar; 53(3):818-826. PubMed ID: 33219624
[TBL] [Abstract][Full Text] [Related]
27. Background parenchymal enhancement on baseline screening breast MRI: impact on biopsy rate and short-interval follow-up.
Hambly NM; Liberman L; Dershaw DD; Brennan S; Morris EA
AJR Am J Roentgenol; 2011 Jan; 196(1):218-24. PubMed ID: 21178070
[TBL] [Abstract][Full Text] [Related]
28. Factors Associated With Background Parenchymal Enhancement on Contrast-Enhanced Mammography.
Karimi Z; Phillips J; Slanetz P; Lotfi P; Dialani V; Karimova J; Mehta T
AJR Am J Roentgenol; 2021 Feb; 216(2):340-348. PubMed ID: 32755162
[No Abstract] [Full Text] [Related]
29. Ovarian cysts in tamoxifen-treated women with breast cancer.
Inal MM; Incebiyik A; Sanci M; Yildirim Y; Polat M; Pilanci B; Nayki C; Camuzcuoğlu H
Eur J Obstet Gynecol Reprod Biol; 2005 May; 120(1):104-6. PubMed ID: 15866095
[TBL] [Abstract][Full Text] [Related]
30. Automated fibroglandular tissue segmentation in breast MRI using generative adversarial networks.
Ma X; Wang J; Zheng X; Liu Z; Long W; Zhang Y; Wei J; Lu Y
Phys Med Biol; 2020 May; 65(10):105006. PubMed ID: 32155611
[TBL] [Abstract][Full Text] [Related]
31. Overexpression of p53 is correlated with poor outcome in premenopausal women with breast cancer treated with tamoxifen after chemotherapy.
Kim HS; Yom CK; Kim HJ; Lee JW; Sohn JH; Kim JH; Park YL; Ahn SH
Breast Cancer Res Treat; 2010 Jun; 121(3):777-88. PubMed ID: 19806450
[TBL] [Abstract][Full Text] [Related]
32. The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancer.
Albert M; Schnabel F; Chun J; Schwartz S; Lee J; Klautau Leite AP; Moy L
Clin Imaging; 2015; 39(6):987-92. PubMed ID: 26351036
[TBL] [Abstract][Full Text] [Related]
33. Background parenchymal enhancement at breast MR imaging: normal patterns, diagnostic challenges, and potential for false-positive and false-negative interpretation.
Giess CS; Yeh ED; Raza S; Birdwell RL
Radiographics; 2014; 34(1):234-47. PubMed ID: 24428293
[TBL] [Abstract][Full Text] [Related]
34. [Tamoxifen adjuvant delays early breast cancer. Results of a cooperative randomized trial].
Delozier T; Switsers O; Génot JY; Ollivier JM; Héry M; Namer M; Frenay M; Kerbrat P; Julien JP; Naja A; Janvier M; Macé-Lesec'h J
Bull Cancer; 1997 Jan; 84(1):25-30. PubMed ID: 9180855
[TBL] [Abstract][Full Text] [Related]
35. Comparison of 3-point Dixon imaging and fuzzy C-means clustering methods for breast density measurement.
Clendenen TV; Zeleniuch-Jacquotte A; Moy L; Pike MC; Rusinek H; Kim S
J Magn Reson Imaging; 2013 Aug; 38(2):474-81. PubMed ID: 23292922
[TBL] [Abstract][Full Text] [Related]
36. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
37. Effect of adjuvant systemic treatment on cosmetic outcome and late normal-tissue reactions after breast conservation.
Johansen J; Overgaard J; Overgaard M
Acta Oncol; 2007; 46(4):525-33. PubMed ID: 17497320
[TBL] [Abstract][Full Text] [Related]
38. Relationship Between Breast Ultrasound Background Echotexture and Magnetic Resonance Imaging Background Parenchymal Enhancement and the Effect of Hormonal Status Thereon.
Kim SJ; Jung HK; Han BK; Lee JH; Oh KS; Lee JS; Lee Y
Ultrasound Q; 2020 Jun; 36(2):179-191. PubMed ID: 32511210
[TBL] [Abstract][Full Text] [Related]
39. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
[TBL] [Abstract][Full Text] [Related]
40. Risk of early recurrence among postmenopausal women with estrogen receptor-positive early breast cancer treated with adjuvant tamoxifen.
Kennecke H; McArthur H; Olivotto IA; Speers C; Bajdik C; Chia SK; Ellard S; Norris B; Hayes M; Barnett J; Gelmon KA
Cancer; 2008 Apr; 112(7):1437-44. PubMed ID: 18286526
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
